

**WPS Government Health Administrators  
Contractor Advisory Committee (CAC) Meeting**

**Moderator: Dr. Ella Noel**

**June 28<sup>th</sup>, 2021**

**5:00 PM CT (6:00 PM ET)**

OPERATOR: This is Conference # 5965777

Dr. Ella Noel: Hi, I'd like to welcome everyone to the J8 Medicare Administrative Contractor Advisory Committee Meeting. This is Dr. Ella Noel, I'm one of the J8 Contractor Medical Directors at WPS.

Tonight, we are going to take information and comments on 5 policies or LCD. And that will occur during the open portion of the meeting. After that, we will limit the meeting to the CAC members only and we will finish up with our private educational meeting.

So, we're going to go ahead and get started with the draft. The first draft is the Botulinum Toxin Type A and type B, it is DL34635. Dr. Kettler is the lead CMD on this policy. This is a revision of the current LCD with updates with the definition of chronic migraine headaches and achalasia, and added information under the summary of evidence.

This LCD contains a single list of accepted indications for the four current toxins commercially available in USA. The provider is expected to know the correct indication whether toxin that they are using. The comment period will end on July 10<sup>th</sup> of 2021.

Does anybody in the CAC membership have any questions or any comments about this draft revision?

(Sadae), do we have anybody who wishes to make a comment?

Operator: And participants if you would like to wish comments, please press star one on your telephone. We don't have anyone to have a comment, please continue.

Dr. Ella Noel: Alright. The next LCD is Cosmetic and Reconstructive Surgery, DL39051. Dr. Kettler is the lead CMD on this policy. This is a revision of the current LCD. It contains a list of indications for specific surgery and a list of non-covered procedures. The comment period will end on July 10<sup>th</sup>, 2021. Does anyone have any comments about this policy?

(Sadae), does anybody wish to make a comment?

Operator: We don't have any comments at this moment.

Dr. Ella Noel: Alright. We will move on to the next policy. This is the last policy for Dr. Kettler at this meeting. It is the Epidural Procedures for Pain Management, DL39054. This LCD lists covered indications along with documentation requirements for the procedures, a list of limitations is also present. Definitions were also supplied. Is there anybody who wishes to comment on this LCD (Sadae)?

Operator: Again, if you would like to make a comment, please press star one on your telephone.

No one wishes to make comments, please continue.

Dr. Ella Noel: Alright. We have several MoIDX policies that we're going to talk about. The first one is MoIDX Biomarkers to Risk-Stratify Patients at Increased Risk for Prostate Cancer, DL39042. I am the lead CMD on the MoIDX policies. This is a foundational policy with limited coverage for prosthetic biomarker diagnostic tests that will help differentiate men who may or may not benefit from a prostate biopsy or repeat biopsy. This LCD will replace multiple individual LCD for this topic. The comment period on the MoIdx LCDs ends on July 3<sup>rd</sup>, 2021. Do we have any comments on this policy?

Operator: Again, if you would like to make comments, please press star one on your telephone.

We don't have any comment this time, please continue.

Dr. Ella Noel: The next policy is Next Generation Sequencing Lab-Developed Tests for Inherited Cancer Syndromes, DL39040. I am lead CMD on this policy. This LCD describes and clarifies coverage for lab developed tests, FDA cleared and FDA approved laboratory tests utilizing next generation sequencing and hereditary cancer as allowable under NCD 90.2, under section D describing MAC discussion and coverage. Comment period will end on 07/03/2021.

We would ask that you submit any of your comments in writing to [medicarepolicycomments@wpsic.com](mailto:medicarepolicycomments@wpsic.com) by either July 10<sup>th</sup> or July 3<sup>rd</sup> depending on which policy was noted. And then I just wanted to bring to your attention that there were 2 MoIDX LCD that were presented at the open meeting on June 16<sup>th</sup>, 2021, this was done as part of the LCD process.

They were not felt that they needed to be presented formally at the CAC. One of these LCDs with the Melanoma Risk Stratification Molecular Testing, DL38018. This LCD was revised because of some recent publications in this area which has cast doubt on the clinical utility at the test.

The MoIDX JOA MACs are seeking opinions on this policy and that comment period ends on the third of July. The last policy at the open meeting was a MoIDX policy titled Multiplex Nucleic Acid Amplification Test Panels for Infectious Disease Testing, DL39044, and this LCD was presented earlier at multi-jurisdictional CAC involving the MoIDX.

And that one also has a comment period ending July 3rd. Is there a - - at this point in time, we were done with the open portion of the meeting. We are going to be going to the private portion of the meeting and we are going to dismiss the public members who are listening into the program at this point in time and go on our private educational portion of the meeting after this.

So, (Sadae), we may disconnect from the public.

Operator: Again, for the public side, please now disconnect.